Update on reports of suspected adverse reactions to COVID-19 vaccines in Switzerland

14. Oktober 2021 – Until 12 October 2021, Swissmedic evaluated 8,757 reports on suspected adverse drug reactions to COVID-19 vaccinations that occured with a temporal link to the vaccinations. At 5,779 (66 %), most of the reports were classified as not serious, while 2,978 (34 %) reports were classified as serious.

6,021 (68.8%) reports involve Moderna's COVID-19 vaccine Spikevax® (for approx. 66% of the vaccine doses administered - this is the most widely used COVID-19 vaccine in Switzerland), while 2,578 (29.4%) are associated with Pfizer/BioNTech's Comirnaty® (approx. 34% administered vaccine doses). In 158 (1.8%) cases, the vaccine was not specified. The average age of those affected was 53.3 years.

The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile.

For more information see here.